Transitional B lymphocytes are associated with protection from kidney allograft rejection: A prospective study

American Journal of Transplantation

Volumn 15, Issue 5, 2015, Pages 1384-1391

  Shabir, S ^a,b   Girdlestone, J ^c,d   Briggs, D ^e   Kaul, B ^b   Smith, H ^b   Daga, S ^e   Chand, S ^a,b   Jham, S ^a,b   Navarrete, C ^c,d   Harper, L ^a,b   Ball, S ^a,b   Borrows, R ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Histocompatibility and Immunogenetics Research Group   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

kidney disease: immune inflammatory; kidney transplantation nephrology; rejection: acute; rejection: antibody mediated (ABMR); translational research science

Indexed keywords

BASILIXIMAB; COTRIMOXAZOLE; ISONIAZID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; ANTIBODY; BIOLOGICAL MARKER; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIBODY SCREENING; ARTICLE; CELL POPULATION; CELLULAR IMMUNITY; CYTOTOXICITY; DELAYED GRAFT FUNCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RENAL PROTECTION; TREATMENT REFUSAL; B LYMPHOCYTE; BIOPSY; CHEMISTRY; CYTOLOGY; GRAFT REJECTION; KIDNEY TRANSPLANTATION; METABOLISM; MIDDLE AGED; PATIENT COMPLIANCE; RENAL INSUFFICIENCY; TIME; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

ADULT; ANTIBODIES; B-LYMPHOCYTES; BIOMARKERS; BIOPSY; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHENOTYPE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; TIME FACTORS; TRANSPLANT RECIPIENTS; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 84928034389     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13122     Document Type: Article

References (28)

1. Katz SI, Parker D, Turk JL.; B cell suppression of delayed hypersensitivity reactions. Nature. 1974; 251: 550-551.
2. Neta R, Salvin SB.; Specific suppression of delayed hypersensitivity: The possible presence of a suppressor B cell in the regulation of delayed hypersensitivity. J Immunol 1974; 113: 1716-1725.
3. Blair PA, Noreña LY, Flores-Borja F, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010; 32: 129-140.
4. Duddy M, Niino M, Adatia F, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178: 6092-6099.
5. Newell KA, Asare A, Kirk AD, et al. Immune Tolerance Network ST507 Study Group. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836-1847.
6. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120: 1848-1861.
7. Chesneau M, Pallier A, Braza F, et al. Unique B cell differentiation profile in tolerant kidney transplant patients. Am J Transplant 2014; 14: 144-155.
8. Stolp J, Turka LA, Wood KJ.; B cells with immune-regulating function in transplantation. Nat Rev Nephrol 2014; 10: 389-397.
9. Cherukuri A, Rothstein DM, Clark B, et al. Immunologic human renal allograft injury associates with an altered IL-10/TNF-α expression ratio in regulatory B cells. J Am Soc Nephrol 2014; 25: 1575-1585.
10. Nouël A, Ségalen I, Jamin C, et al. B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody-mediated rejection. Kidney Int 2014; 85: 590-599.
11. Hanvesakul R, Maillere B, Briggs D, Baker R, Larché M, Ball S.; Indirect recognition of T cell epitopes derived from the alpha 3 and transmembrane domain of HLA-A2. Am J Transplant 2007; 7: 1148-1157.
12. Smith HJ, Hanvesakul R, Bentall A, et al. T Lymphocyte responses to nonpolymorphic HLA-derived peptides are associated with chronic renal allograft dysfunction. Transplantation 2011; 91: 279-286.
13. Smith HJ, Hanvesakul R, Morgan MD, et al. Chronic graft versus host disease is associated with an immune response to autologous human leukocyte antigen-derived peptides. Transplantation 2010; 90: 555-563.
14. Pourhoseingholi MA, Hajizadeh E, Moghimi Dehkordi B, Safaee A, Abadi A, Zali MR.; Comparing Cox regression and parametric models for survival of patients with gastric carcinoma. Asian Pac J Cancer Prev 2007; 8: 412-416.
15. El Ters M, Grande JP, Keddis MT, et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant 2013; 13: 2334-2341.
16. Lentine KL, Gheorghian A, Axelrod D, Kalsekar A, L'italien G, Schnitzler MA.; The implications of acute rejection for allograft survival in contemporary U.S. kidney transplantation. Transplantation 2012; 94: 369-376.
17. Shabir S, Halimi JM, Cherukuri A, et al. Predicting 5-year risk of kidney transplant failure: A prediction instrument using data available at 1 year posttransplantation. Am J Kidney Dis 2014; 63: 643-651.
18. Hayde N, Broin PO, Bao Y, et al. Increased intragraft rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. Kidney Int 2014; 86: 600-609.
19. Cooper JE, Gralla J, Chan L, Wiseman AC.; Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl 2011; 359-364.
20. Bartel G, Regele H, Wahrmann M, et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 2008; 8: 2652-2660.
21. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
22. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
23. Hayde N, Bao Y, Pullman J, et al. The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy. Clin J Am Soc Nephrol 2013; 8: 2141-2148.
24. Dorling A, Rebollo-Mesa I, Hilton R, et al. Can a combined screening/treatment programme prevent premature failure of renal transplants due to chronic rejection in patients with HLA antibodies: Study protocol for the multicentre randomised controlled OuTSMART trial. Trials 2014; 15: 30.
25. Moreso F, Carrera M, Goma M, et al. Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation 2012; 93: 41-46.
26. Gill JS, Landsberg D, Johnston O, et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. Transplantation 2010; 89: 178-184.
27. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC.; Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation 2011; 91: 1103-1109.
28. Heilman RL, Nijim A, Desmarteau YM, et al. De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation. Transplantation 2014; 98: 1310-1315.